JP2015500333A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015500333A5 JP2015500333A5 JP2014546729A JP2014546729A JP2015500333A5 JP 2015500333 A5 JP2015500333 A5 JP 2015500333A5 JP 2014546729 A JP2014546729 A JP 2014546729A JP 2014546729 A JP2014546729 A JP 2014546729A JP 2015500333 A5 JP2015500333 A5 JP 2015500333A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- subject
- group
- composition according
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 8
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 8
- 239000011575 calcium Substances 0.000 claims description 7
- 229910052791 calcium Inorganic materials 0.000 claims description 7
- 208000000038 Hypoparathyroidism Diseases 0.000 claims description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 4
- 206010025476 Malabsorption Diseases 0.000 claims description 3
- 208000004155 Malabsorption Syndromes Diseases 0.000 claims description 3
- 230000002496 gastric effect Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 24
- 239000003381 stabilizer Substances 0.000 claims 8
- 150000001413 amino acids Chemical class 0.000 claims 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 150000002894 organic compounds Chemical class 0.000 claims 4
- 229940122361 Bisphosphonate Drugs 0.000 claims 3
- 150000004663 bisphosphonates Chemical group 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 150000002148 esters Chemical class 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 150000007524 organic acids Chemical class 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 claims 2
- 229940078581 Bone resorption inhibitor Drugs 0.000 claims 2
- 241000238424 Crustacea Species 0.000 claims 2
- 229940062527 alendronate Drugs 0.000 claims 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 2
- 150000002016 disaccharides Chemical class 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 150000004676 glycans Chemical class 0.000 claims 2
- 150000002772 monosaccharides Chemical class 0.000 claims 2
- 229920001542 oligosaccharide Polymers 0.000 claims 2
- 150000002482 oligosaccharides Chemical class 0.000 claims 2
- 235000005985 organic acids Nutrition 0.000 claims 2
- 229920005862 polyol Polymers 0.000 claims 2
- 150000003077 polyols Chemical class 0.000 claims 2
- 229920001282 polysaccharide Polymers 0.000 claims 2
- 239000005017 polysaccharide Substances 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 150000004043 trisaccharides Chemical class 0.000 claims 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims 1
- 208000004300 Atrophic Gastritis Diseases 0.000 claims 1
- 206010004542 Bezoar Diseases 0.000 claims 1
- 208000018083 Bone metabolism disease Diseases 0.000 claims 1
- 229920002101 Chitin Polymers 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 claims 1
- 208000036495 Gastritis atrophic Diseases 0.000 claims 1
- 206010062624 High turnover osteopathy Diseases 0.000 claims 1
- 208000029663 Hypophosphatemia Diseases 0.000 claims 1
- 208000034767 Hypoproteinaemia Diseases 0.000 claims 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000029725 Metabolic bone disease Diseases 0.000 claims 1
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 102000015636 Oligopeptides Human genes 0.000 claims 1
- 108010038807 Oligopeptides Proteins 0.000 claims 1
- 208000010191 Osteitis Deformans Diseases 0.000 claims 1
- 208000002624 Osteitis Fibrosa Cystica Diseases 0.000 claims 1
- 206010049088 Osteopenia Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 208000027067 Paget disease of bone Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 208000026980 Renal tubular disease Diseases 0.000 claims 1
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 claims 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 1
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 claims 1
- 206010047626 Vitamin D Deficiency Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 claims 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 claims 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 229940125681 anticonvulsant agent Drugs 0.000 claims 1
- 239000001961 anticonvulsive agent Substances 0.000 claims 1
- 208000016738 bone Paget disease Diseases 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 230000004097 bone metabolism Effects 0.000 claims 1
- 208000015202 calcium metabolic disease Diseases 0.000 claims 1
- 150000001735 carboxylic acids Chemical class 0.000 claims 1
- 239000002738 chelating agent Substances 0.000 claims 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 229950006137 dexfosfoserine Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940009626 etidronate Drugs 0.000 claims 1
- 229940015872 ibandronate Drugs 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 235000011090 malic acid Nutrition 0.000 claims 1
- 239000001630 malic acid Substances 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000011164 ossification Effects 0.000 claims 1
- 201000008972 osteitis fibrosa Diseases 0.000 claims 1
- 208000005368 osteomalacia Diseases 0.000 claims 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 claims 1
- 229940046231 pamidronate Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 235000021317 phosphate Nutrition 0.000 claims 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 claims 1
- USRGIUJOYOXOQJ-GBXIJSLDSA-N phosphothreonine Chemical compound OP(=O)(O)O[C@H](C)[C@H](N)C(O)=O USRGIUJOYOXOQJ-GBXIJSLDSA-N 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 229940126409 proton pump inhibitor Drugs 0.000 claims 1
- 239000000612 proton pump inhibitor Substances 0.000 claims 1
- 208000014318 renal tubule disease Diseases 0.000 claims 1
- 208000007442 rickets Diseases 0.000 claims 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims 1
- 229960001225 rifampicin Drugs 0.000 claims 1
- 229940089617 risedronate Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 235000002906 tartaric acid Nutrition 0.000 claims 1
- 239000011975 tartaric acid Substances 0.000 claims 1
- 229940019375 tiludronate Drugs 0.000 claims 1
- -1 zolendronate Chemical compound 0.000 claims 1
- 229940069978 calcium supplement Drugs 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009246 food effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161569805P | 2011-12-13 | 2011-12-13 | |
| US61/569,805 | 2011-12-13 | ||
| US201261680721P | 2012-08-08 | 2012-08-08 | |
| US61/680,721 | 2012-08-08 | ||
| PCT/IL2012/050521 WO2013088440A1 (en) | 2011-12-13 | 2012-12-13 | Amorphous calcium carbonate for the treatment of calcium malabsorption and metabolic bone disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018089672A Division JP2018138591A (ja) | 2011-12-13 | 2018-05-08 | カルシウム吸収不良及び代謝性骨障害を治療するための非晶質炭酸カルシウム |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015500333A JP2015500333A (ja) | 2015-01-05 |
| JP2015500333A5 true JP2015500333A5 (enExample) | 2017-03-30 |
Family
ID=48611949
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014546729A Pending JP2015500333A (ja) | 2011-12-13 | 2012-12-13 | カルシウム吸収不良及び代謝性骨障害を治療するための非晶質炭酸カルシウム |
| JP2018089672A Pending JP2018138591A (ja) | 2011-12-13 | 2018-05-08 | カルシウム吸収不良及び代謝性骨障害を治療するための非晶質炭酸カルシウム |
| JP2019181138A Pending JP2019214631A (ja) | 2011-12-13 | 2019-10-01 | カルシウム吸収不良及び代謝性骨障害を治療するための非晶質炭酸カルシウム |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018089672A Pending JP2018138591A (ja) | 2011-12-13 | 2018-05-08 | カルシウム吸収不良及び代謝性骨障害を治療するための非晶質炭酸カルシウム |
| JP2019181138A Pending JP2019214631A (ja) | 2011-12-13 | 2019-10-01 | カルシウム吸収不良及び代謝性骨障害を治療するための非晶質炭酸カルシウム |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10064890B2 (enExample) |
| EP (1) | EP2790710B1 (enExample) |
| JP (3) | JP2015500333A (enExample) |
| CN (2) | CN104114179A (enExample) |
| AU (3) | AU2012354056B2 (enExample) |
| CA (2) | CA3056570C (enExample) |
| DK (1) | DK2790710T3 (enExample) |
| ES (1) | ES2831699T3 (enExample) |
| IL (2) | IL233107B (enExample) |
| WO (1) | WO2013088440A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150374747A1 (en) * | 2013-02-11 | 2015-12-31 | Amorphical Ltd. | Amorphous calcium carbonate for accelerated bone growth |
| EP3174828A4 (en) * | 2014-07-31 | 2018-01-17 | Amorphical Ltd. | Non-aqueous liquid and semi-solid formulations of amorphous calcium carbonate |
| RU2748976C2 (ru) * | 2015-06-04 | 2021-06-02 | Аморфикал Лтд. | Композиции аморфного карбоната кальция для ингаляции, подъязычного или трансбуккального введения |
| US12121538B2 (en) | 2015-06-04 | 2024-10-22 | Amorphical Ltd. | Compositions of amorphous calcium carbonate for inhalation, sublingual or buccal administration |
| JP2017032550A (ja) * | 2015-07-30 | 2017-02-09 | 大塚製薬株式会社 | 胃粘膜萎縮の有無を判定する方法 |
| JP6873389B2 (ja) | 2016-01-18 | 2021-05-19 | アモーフィカル リミテッド． | 神経学的、筋肉、および不妊の疾患または症状の治療のための安定化無定形炭酸カルシウム |
| CN108778295A (zh) | 2016-01-18 | 2018-11-09 | 艾玛菲克有限公司 | 作为细胞培养基补充剂的稳定的无定形碳酸钙 |
| US20230365935A1 (en) * | 2016-01-18 | 2023-11-16 | Amorphical Ltd. | Stabilized amorphous calcium carbonate as a supplement for cell culture media |
| JP6872680B2 (ja) * | 2016-03-22 | 2021-05-19 | 国立大学法人 宮崎大学 | カルシウム吸収促進剤 |
| US11052108B2 (en) | 2016-10-25 | 2021-07-06 | Amorphical Ltd. | Amorphous calcium carbonate for treating a leukemia |
| CN110123836A (zh) * | 2019-05-20 | 2019-08-16 | 昆明朗盛生物科技有限公司 | 钙锌维生素d泛酸片的应用 |
| CA3144221A1 (en) | 2019-07-23 | 2021-01-28 | Amorphical Ltd | Amorphous calcium carbonate for improving athletic performance |
| EP4117685A4 (en) * | 2020-03-11 | 2024-03-20 | Amorphical Ltd. | AMORPHOUS CALCIUM CARBONATE FOR THE TREATMENT OF ACIDOSIS |
| WO2021226064A1 (en) * | 2020-05-04 | 2021-11-11 | University Of Louisville Research Foundation, Inc. | Artificial intelligence-based systems and methods for dosing of pharmacologic agents |
| WO2022058337A1 (en) * | 2020-09-15 | 2022-03-24 | Oncoinvent As | Size controlled radiolabelled particles |
| JP7573310B2 (ja) * | 2022-02-28 | 2024-10-25 | 一般社団法人 Unical | ヒトによる経口摂取のためのカルシウム組成物 |
| EP4615802A1 (en) * | 2022-11-08 | 2025-09-17 | Amorphical Ltd. | Methods for preparing amorphous calcium carbonate by fixation of carbon dioxide |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL87452A (en) | 1987-08-28 | 1992-07-15 | Norwich Eaton Pharma | Calcium citrate malate and calcium supplements containing it |
| CA1336328C (en) | 1988-04-11 | 1995-07-18 | Walter G. Leonard | Method of increasing bone density in humans |
| AU1366697A (en) | 1995-12-26 | 1997-07-28 | Holomed Aps | A method and system for generating an x-ray image |
| JPH10236957A (ja) | 1997-02-24 | 1998-09-08 | Bankaku Souhonpo:Kk | 骨粗鬆症の改善剤 |
| SE9702401D0 (sv) * | 1997-06-19 | 1997-06-19 | Astra Ab | Pharmaceutical use |
| JP2003292453A (ja) | 2002-04-02 | 2003-10-15 | Asahi Kasei Corp | 骨疾患治療用医薬複合剤 |
| US7267832B2 (en) * | 2004-02-18 | 2007-09-11 | Kraft Foods Holdings, Inc. | Amorphous water-soluble calcium citrate salts and method of making and using same |
| EP1758599B1 (en) * | 2004-05-26 | 2013-11-27 | Ben Gurion University Of The Negev Research And Development Authority | Orally-administrable compositions comprising stable amorphous calcium carbonate |
| US20070041506A1 (en) | 2005-08-22 | 2007-02-22 | Michelle Bottino | Digital sensor holder |
| GB0522045D0 (en) | 2005-10-28 | 2005-12-07 | Novartis Ag | Pharmaceutical compositions |
| IL178495A (en) * | 2006-10-05 | 2014-12-31 | Univ Ben Gurion | Use of cancerous gastric components or artificial calcium containing carbonate, chitin and polypeptide preparations to treat calcium metabolism-related or calcium-signaling conditions |
| ES2528901T3 (es) * | 2007-10-22 | 2015-02-13 | Amorphical Ltd. | Carbonato de calcio amorfo estable que comprende aminoácidos fosforilados, péptidos fosforilados sintéticos y proteínas gastrolíticas |
| WO2009087553A1 (en) * | 2008-01-02 | 2009-07-16 | Aurobindo Pharma Limited | Kits for administering bisphosphonates |
| CN101314031A (zh) | 2008-07-14 | 2008-12-03 | 王冰 | 一种改善骨营养的制剂 |
| JP2012505728A (ja) * | 2008-10-17 | 2012-03-08 | フレゼニウス メディカル ケア ホールディングス インコーポレイテッド | 透析患者のためのリン結合剤投与量の決定方法 |
| CN102085356B (zh) | 2010-12-28 | 2013-02-27 | 北京同仁堂健康药业股份有限公司 | 一种用于增加骨密度的组合物及其制备方法 |
-
2012
- 2012-12-13 US US14/364,992 patent/US10064890B2/en active Active
- 2012-12-13 CA CA3056570A patent/CA3056570C/en active Active
- 2012-12-13 JP JP2014546729A patent/JP2015500333A/ja active Pending
- 2012-12-13 WO PCT/IL2012/050521 patent/WO2013088440A1/en not_active Ceased
- 2012-12-13 AU AU2012354056A patent/AU2012354056B2/en active Active
- 2012-12-13 CA CA2859122A patent/CA2859122C/en active Active
- 2012-12-13 ES ES12857932T patent/ES2831699T3/es active Active
- 2012-12-13 CN CN201280069595.5A patent/CN104114179A/zh active Pending
- 2012-12-13 DK DK12857932.3T patent/DK2790710T3/da active
- 2012-12-13 EP EP12857932.3A patent/EP2790710B1/en active Active
- 2012-12-13 CN CN201910013584.9A patent/CN109568338A/zh active Pending
-
2014
- 2014-06-12 IL IL233107A patent/IL233107B/en active IP Right Grant
-
2017
- 2017-12-28 AU AU2017279824A patent/AU2017279824A1/en not_active Abandoned
-
2018
- 2018-05-08 JP JP2018089672A patent/JP2018138591A/ja active Pending
- 2018-07-31 US US16/050,651 patent/US10688124B2/en active Active
-
2019
- 2019-10-01 JP JP2019181138A patent/JP2019214631A/ja active Pending
-
2020
- 2020-01-31 AU AU2020200704A patent/AU2020200704A1/en not_active Abandoned
- 2020-05-18 IL IL274755A patent/IL274755B/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015500333A5 (enExample) | ||
| JP6750076B2 (ja) | カルビドパおよびｌ−ドーパプロドラッグならびにそれらの使用方法 | |
| Russell | Bisphosphonates: the first 40 years | |
| Russell | Bisphosphonates: mode of action and pharmacology | |
| US6943155B2 (en) | Unique compositions of zwitterionic phospholipids and bisphosphonates and use of the compositions as bisphosphate delivery systems with reduced GI toxicity | |
| Ezra et al. | Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption | |
| CN103908455A (zh) | 肌醇六磷酸酯用于预防骨质疏松症的应用 | |
| HRP20161170T1 (hr) | Pripravak tekućine za dijalizu koji sadrži tvari za inhibiciju kristalizacije | |
| US20250302853A1 (en) | Ip and ip analogs dosage regimens for the treatment of ectopic calcifications | |
| US20070088161A1 (en) | Novel chelated bisphosphonates for use as pharmaceutical agents | |
| US20250276991A1 (en) | Processes for the preparation of soluble salts of inositol phosphates | |
| Breuer | The development of bisphosphonates as drugs | |
| JP2010539231A (ja) | 悪液質の治療のための方法および手段 | |
| CN110121351A (zh) | 用于治疗白血病的无定形碳酸钙 | |
| WO2017131127A1 (ja) | 新規ビスホスホン酸化合物 | |
| Fleisch | Bisphosphonates | |
| WO2024246896A1 (en) | Amorphous calcium carbonate for prevention and treatment of myocardial ischemia | |
| JP2009508834A5 (enExample) | ||
| US8623845B1 (en) | Pharmaceutical composition for preventing or treating Diabetes mellitus comprising bisphophonates | |
| Neldi | Zoledronic acid use and adverse drug reaction (ADR) | |
| Henk et al. | Clinical findings and main considerations of the use of bisphosphonate in dental implants: a concise systematic review | |
| Bone | Bisphosphonate therapy for postmenopausal osteoporosis | |
| WO2006133097A2 (en) | Use of alternating amine and non-amine bisphosphonate combinations for treating osteoporosis | |
| PL217023B1 (pl) | Zastosowanie kwasu fenylo-1,4-diaminobis(metylidenobisfosfonowego) do wytwarzania preparatu farmaceutycznego |